281 related articles for article (PubMed ID: 12820253)
1. Application and limitations of X-ray crystallographic data in structure-based ligand and drug design.
Davis AM; Teague SJ; Kleywegt GJ
Angew Chem Int Ed Engl; 2003 Jun; 42(24):2718-36. PubMed ID: 12820253
[TBL] [Abstract][Full Text] [Related]
2. Structure-based development of target-specific compound libraries.
Orry AJ; Abagyan RA; Cavasotto CN
Drug Discov Today; 2006 Mar; 11(5-6):261-6. PubMed ID: 16580603
[TBL] [Abstract][Full Text] [Related]
3. Analysis and optimization of structure-based virtual screening protocols. (3). New methods and old problems in scoring function design.
Smith R; Hubbard RE; Gschwend DA; Leach AR; Good AC
J Mol Graph Model; 2003 Sep; 22(1):41-53. PubMed ID: 12798390
[TBL] [Abstract][Full Text] [Related]
4. Importance of molecular computer modeling in anticancer drug development.
Geromichalos GD
J BUON; 2007 Sep; 12 Suppl 1():S101-18. PubMed ID: 17935268
[TBL] [Abstract][Full Text] [Related]
5. E-novo: an automated workflow for efficient structure-based lead optimization.
Pearce BC; Langley DR; Kang J; Huang H; Kulkarni A
J Chem Inf Model; 2009 Jul; 49(7):1797-809. PubMed ID: 19552372
[TBL] [Abstract][Full Text] [Related]
6. Supervised scoring models with docked ligand conformations for structure-based virtual screening.
Teramoto R; Fukunishi H
J Chem Inf Model; 2007; 47(5):1858-67. PubMed ID: 17685604
[TBL] [Abstract][Full Text] [Related]
7. A detailed comparison of current docking and scoring methods on systems of pharmaceutical relevance.
Perola E; Walters WP; Charifson PS
Proteins; 2004 Aug; 56(2):235-49. PubMed ID: 15211508
[TBL] [Abstract][Full Text] [Related]
8. High-throughput X-ray crystallography for drug discovery.
Blundell TL; Patel S
Curr Opin Pharmacol; 2004 Oct; 4(5):490-6. PubMed ID: 15351354
[TBL] [Abstract][Full Text] [Related]
9. HierVLS hierarchical docking protocol for virtual ligand screening of large-molecule databases.
Floriano WB; Vaidehi N; Zamanakos G; Goddard WA
J Med Chem; 2004 Jan; 47(1):56-71. PubMed ID: 14695820
[TBL] [Abstract][Full Text] [Related]
10. Structural interaction fingerprint (SIFt): a novel method for analyzing three-dimensional protein-ligand binding interactions.
Deng Z; Chuaqui C; Singh J
J Med Chem; 2004 Jan; 47(2):337-44. PubMed ID: 14711306
[TBL] [Abstract][Full Text] [Related]
11. Fragment-based drug discovery applied to Hsp90. Discovery of two lead series with high ligand efficiency.
Murray CW; Carr MG; Callaghan O; Chessari G; Congreve M; Cowan S; Coyle JE; Downham R; Figueroa E; Frederickson M; Graham B; McMenamin R; O'Brien MA; Patel S; Phillips TR; Williams G; Woodhead AJ; Woolford AJ
J Med Chem; 2010 Aug; 53(16):5942-55. PubMed ID: 20718493
[TBL] [Abstract][Full Text] [Related]
12. Structural requirements for factor Xa inhibition by 3-oxybenzamides with neutral P1 substituents: combining X-ray crystallography, 3D-QSAR, and tailored scoring functions.
Matter H; Will DW; Nazaré M; Schreuder H; Laux V; Wehner V
J Med Chem; 2005 May; 48(9):3290-312. PubMed ID: 15857135
[TBL] [Abstract][Full Text] [Related]
13. Structure-based approaches to drug design and virtual screening.
Waszkowycz B
Curr Opin Drug Discov Devel; 2002 May; 5(3):407-13. PubMed ID: 12058616
[TBL] [Abstract][Full Text] [Related]
14. Comparative evaluation of eight docking tools for docking and virtual screening accuracy.
Kellenberger E; Rodrigo J; Muller P; Rognan D
Proteins; 2004 Nov; 57(2):225-42. PubMed ID: 15340911
[TBL] [Abstract][Full Text] [Related]
15. Characterization of protein-ligand interaction sites using experimental and computational methods.
Vajda S; Guarnieri F
Curr Opin Drug Discov Devel; 2006 May; 9(3):354-62. PubMed ID: 16729732
[TBL] [Abstract][Full Text] [Related]
16. Prediction of binding modes for ligands in the cytochromes P450 and other heme-containing proteins.
Kirton SB; Murray CW; Verdonk ML; Taylor RD
Proteins; 2005 Mar; 58(4):836-44. PubMed ID: 15651036
[TBL] [Abstract][Full Text] [Related]
17. LigEvolutioner, a new strategy for modification and optimization of lead compounds in receptor/ligand complexes.
Zhou P; Tian F; Shang Z
Chem Biol Drug Des; 2008 Dec; 72(6):525-32. PubMed ID: 19090919
[TBL] [Abstract][Full Text] [Related]
18. Towards in silico lead optimization: scores from ensembles of protein/ligand conformations reliably correlate with biological activity.
Popov VM; Yee WA; Anderson AC
Proteins; 2007 Feb; 66(2):375-87. PubMed ID: 17078091
[TBL] [Abstract][Full Text] [Related]
19. Automated protein-ligand crystallography for structure-based drug design.
Mooij WT; Hartshorn MJ; Tickle IJ; Sharff AJ; Verdonk ML; Jhoti H
ChemMedChem; 2006 Aug; 1(8):827-38. PubMed ID: 16902937
[TBL] [Abstract][Full Text] [Related]
20. EADock: docking of small molecules into protein active sites with a multiobjective evolutionary optimization.
Grosdidier A; Zoete V; Michielin O
Proteins; 2007 Jun; 67(4):1010-25. PubMed ID: 17380512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
